AbZelectPRO™: Enhanced Cell Line Development Platform

By Brett Verstak, Blanca San Miguel, Oscar Swindley , Nathan Courtier, Kean Huedepohl, Ned Swift, Miles Wellington, Sophie Douglas, Noah Collins, Elizabeth Willows, Tania Fisher, Kalpana Wood, Tanya Knight, Beata Blaszczyk, and Nicole Wakes

Our fully integrated AbZelectPRO™ platform accelerates the generation of robust, high-yielding cell lines for even the most complex biologics and bioconjugates. By combining our proprietary CHO-K1 mammalian cell line with ProteoNic’s advanced 2G UNic® premium vector technology and a finely optimized process, AbZelectPRO™ achieves rapid cell doubling, enhanced stability, and industry-leading productivity of up to 10 g/L. This powerful platform enables efficient production not only of antibodies but also of traditionally hard-to-express molecules, including fusion proteins, bispecifics, vaccines, and next-generation therapeutic modalities.

Leveraging Abzena’s deep expertise in biologics development and supported by our comprehensive analytics suite, AbZelectPRO™ streamlines the IND application pathway, ensuring smooth progression into clinical phases. Moreover, with Early Material Generation from Stable Pools, the platform removes downstream method development and formulation from the CLD critical path, offering clients the flexibility to accelerate timelines or use this capability as a stand-alone solution.